The Malaria Vaccine Candidate GMZ2 Elicits Functional Antibodies in Individuals From Malaria Endemic and Non-Endemic Areas | Zendy

Micha Phill Grønholm Jepsen | Zendy; Prajakta Jogdand | Zendy; Susheel Kumar Singh | Zendy; Meral Esen | Zendy; Michael Christiansen | Zendy; Saadou Issifou | Zendy; Aurore Bouyoukou Hounkpatin | Zendy; Ulysse Ateba-Ngoa | Zendy; Peter G. Kremsner | Zendy; Morten Hanefeld Dziegiel | Zendy; S. Olesen-Larsen | Zendy; Søren Jepsen | Zendy; Benjamin Mordmüller | Zendy; Michael Theisen | Zendy

Open Access

The Malaria Vaccine Candidate GMZ2 Elicits Functional Antibodies in Individuals From Malaria Endemic and Non-Endemic Areas

Author(s) -

Micha Phill Grønholm Jepsen,

Prajakta Jogdand,

Susheel Kumar Singh,

Meral Esen,

Michael Christiansen,

Saadou Issifou,

Aurore Bouyoukou Hounkpatin,

Ulysse Ateba-Ngoa,

Peter G. Kremsner,

Morten Hanefeld Dziegiel,

S. Olesen-Larsen,

Søren Jepsen,

Benjamin Mordmüller,

Michael Theisen

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit185

Subject(s) - malaria vaccine , malaria , immunogenicity , vaccination , antibody , plasmodium falciparum , immunology , biology , virology , immunoglobulin g , subclass , medicine

GMZ2 is a hybrid protein consisting of the N-terminal region of the glutamate-rich protein fused in frame to the C-terminal region of merozoite surface protein 3 (MSP3). GMZ2 formulated in Al(OH)3 has been tested in 3 published phase 1 clinical trials. The GMZ2/alum formulation showed good safety, tolerability, and immunogenicity, but whether antibodies elicited by vaccination are functional is not known.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research